- Home
- MLCO vs SLNO Comparison
MLCO vs SLNO Comparison
Compare MLCO & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLCO
- SLNO
- Stock Information
- Founded
- MLCO 2004
- SLNO 1999
- Country
- MLCO Hong Kong
- SLNO United States
- Employees
- MLCO N/A
- SLNO N/A
- Industry
- MLCO Hotels/Resorts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MLCO Consumer Discretionary
- SLNO Health Care
- Exchange
- MLCO Nasdaq
- SLNO Nasdaq
- Market Cap
- MLCO 3.2B
- SLNO 3.7B
- IPO Year
- MLCO 2006
- SLNO 2014
- Fundamental
- Price
- MLCO $8.97
- SLNO $48.49
- Analyst Decision
- MLCO Buy
- SLNO Strong Buy
- Analyst Count
- MLCO 6
- SLNO 9
- Target Price
- MLCO $10.08
- SLNO $114.89
- AVG Volume (30 Days)
- MLCO 2.6M
- SLNO 2.3M
- Earning Date
- MLCO 11-06-2025
- SLNO 11-04-2025
- Dividend Yield
- MLCO N/A
- SLNO N/A
- EPS Growth
- MLCO N/A
- SLNO N/A
- EPS
- MLCO 0.26
- SLNO N/A
- Revenue
- MLCO $5,061,044,000.00
- SLNO $98,675,000.00
- Revenue This Year
- MLCO $12.67
- SLNO N/A
- Revenue Next Year
- MLCO $3.25
- SLNO $181.30
- P/E Ratio
- MLCO $34.59
- SLNO N/A
- Revenue Growth
- MLCO 11.46
- SLNO N/A
- 52 Week Low
- MLCO $4.55
- SLNO $41.50
- 52 Week High
- MLCO $10.15
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- MLCO 61.41
- SLNO 35.03
- Support Level
- MLCO $7.92
- SLNO $41.80
- Resistance Level
- MLCO $9.32
- SLNO $50.78
- Average True Range (ATR)
- MLCO 0.33
- SLNO 3.62
- MACD
- MLCO 0.13
- SLNO -2.00
- Stochastic Oscillator
- MLCO 77.89
- SLNO 21.82
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.